AKT1 and acute myeloid leukemia: As shown in Figures 8D–F, PKC412 and AC220, which were tested in parallel, resulted in the highest degree of patient cell killing when either drug was used in combination with Akt inhibitors as compared to any single agent against a panel of primary AML samples.